Dow has worst day in six months amid concerns from Ukraine, Portugal and Argentina. U.S. economic data and earnings weighed too.» Read More
The "Fast Money" traders share their final trades of the day.
News that the U.S. economy jumped by 4 percent last quarter is taking the spotlight from a surge in new IPOs coming this week.
One company reported a strong quarter and the other flopped—but CNBC's Jim Cramer thinks both stocks are a buy.
Investors would hope they didn't sell the 13 S&P 500 stocks that have blasted 25% higher or more since May 1. USA Today reports.
Some of the names on the move ahead of the open.
On Tuesday, investors gave earnings from International Paper a Bronx cheer, with shares declining about 1.5 percent after the release.
Several companies missed profit estimates today, bucking the trend. Here's what it means for the markets....
Does your homeowners or renters insurance policy cover unusual perils?
The stock market faces two points of vulnerability that will likely push prices lower, U.S. Trust's Keith Banks says.
Panera Bread and Chipotle have both made names for themselves as healthier fast food chains, but lately their performances and stocks have diverged.
If there is a time to own gold as a safe alternative to other assets during tumultuous times, there's no time like the present.
Though Wall Street awaits the Fed's monetary policy announcement, it's not the "biggest wildcard" this week, says Jefferies analyst David Zervos.
Despite the conflict in Ukraine and the sanctions imposed on Russia, Jim Grant is bullish on Russian stocks.
"It's not just don't put money in bonds. You need to rethink how you put your money in bonds," BlackRock's chief investment strategist for fixed income says.
Check out which companies are making headlines after the bell Tuesday: Twitter, Amgen, American Express & more.
It may sound cliché, but given three developments this stock may be a case of one man’s trash being another man’s treasure.
Don't look now, but European bond investors are sending yields to lows unseen in at least 200 years.
A new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone says.
Some of Tuesday's midday movers:
Billionaire investor Paul Singer also warns of a scenario of "real class warfare."
Get the best of CNBC in your inbox